|

DR-01 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Dren Bio1

Indications

  • Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)1
  • Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)1
  • Systemic EBV1 T-cell Lymphoma, if CD8 Positive1
  • Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma1
  • Primary Cutaneous Gamma-Delta T-Cell Lymphoma1

Birmingham, Alabama1 trial

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Dren Investigational Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.